keyword
MENU ▼
Read by QxMD icon Read
search

Brafv600e

keyword
https://www.readbyqxmd.com/read/28214977/braf-mutated-colorectal-cancer-what-is-the-optimal-strategy-for-treatment
#1
REVIEW
Romain Cohen, Pascale Cervera, Magali Svrcek, Anna Pellat, Chantal Dreyer, Aimery de Gramont, Thierry André
The BRAF activating mutation, harbored by approximately 10% of colorectal cancers (CRC), confers dramatic prognosis to advanced diseases. In early-stage setting, the identification of the BRAF mutation does not impact the therapeutic decision. Yet, the BRAF mutation could be considered as a stratification factor in adjuvant trials, because of its prognostic impact after relapse. Moreover, both BRAF mutation and mismatch repair (MMR) statuses should be determined in all CRC to help identify sporadic tumors versus Lynch syndrome-related tumors...
February 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28214213/the-relationship-between-brafv600e-nf-%C3%AE%C2%BAb-and-tgab-expression-in-papillary-thyroid-carcinoma
#2
Wei Li, Hui Ming, Danyang Sun, Wei Li, Dan Wang, Guizhi Zhang, Jian Tan
PURPOSE: The aim of this study was to investigate the potential link between thyroglobulin antibody (TgAb) titers and papillary thyroid carcinoma (PTC) aggressiveness. MATERIALS AND METHODS: This retrospective study included 122 patients who had undergone total thyroidectomy and neck central area lymph dissection followed by radioactive iodine (RAI) ablation for PTC between July 2012 and July 2014. The parameters included clinical characteristics of PTC, TgAb levels and tumor histopathological characteristics...
January 12, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28202513/myeloid-cells-that-impair-immunotherapy-are-restored-in-melanomas-which-acquire-resistance-to-braf-inhibitors
#3
Shannon M Steinberg, Tamer Shabaneh, Peisheng Zhang, Viktor Martyanov, Zhenghui Li, Brian Malik, Tammara Wood, Andrea Boni, Aleksey Molodtsov, Christina V Angeles, Tyler J Curiel, Michael Whitfield, Mary Jo Turk
Acquired resistance to BRAFV600E inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nature of cancers. While there has been significant focus on the cancer cell-intrinsic properties of BRAFi resistance, the impact of BRAFi resistance on host immunity has not been explored. Here we provide preclinical evidence that resistance to BRAFi in an autochthonous mouse model of melanoma is associated with restoration of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment initially reduced by BRAFi treatment...
February 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28192645/cytological-molecular-and-clinical-features-of-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-versus-invasive-forms-of-follicular-variant-of-papillary-thyroid-carcinoma
#4
Liena Zhao, Dora Dias-Santagata, Peter M Sadow, William C Faquin
BACKGROUND: The noninvasive follicular variant of papillary thyroid carcinoma (PTC) has an indolent clinical behavior in comparison with other PTCs, including the invasive follicular variant of papillary thyroid carcinoma (IFVPTC). Recently, the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced to emphasize the low biological potential of these tumors. This study compares clinical, cytological, and molecular features of NIFTP and IFVPTC...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/28181854/effects-of-coexistent-brafv600e-and-tert-promoter-mutations-on-poor-clinical-outcomes-in-papillary-thyroid-cancer-a-meta-analysis
#5
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park
BACKGROUND: Presence of a TERT promoter mutation has been suggested as a potential prognostic marker for thyroid cancer and a synergistic association with the BRAFV600E mutation has been demonstrated. The aim of this study was to verify the role of this genetic duet in papillary thyroid cancer (PTC). METHODS: Studies of the association of BRAFV600E and TERT promoter mutations with clinicopathological features, recurrence, or PTC-related mortality were included from PubMed and Embase databases (inception to September 2016)...
February 9, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28169047/the-mitogen-activated-protein-kinase-pathway-in-melanoma-part-i-activation-and-primary-resistance-mechanisms-to-braf-inhibition
#6
REVIEW
Teresa Amaral, Tobias Sinnberg, Friedegund Meier, Clemens Krepler, Mitchell Levesque, Heike Niessner, Claus Garbe
Mitogen-activated protein kinase (MAPK) pathway has an important role in normal cells and can be activated under physiological conditions. MAPK pathway activation is a fundamental step in several intracellular processes requiring a sequential phosphorylation of the different pathway components. In normal cells, when MAPK pathway activation occurs, it leads to cell growth and differentiation. In order to prevent persistent MAPK pathway activation, physiological upstream negative feedback also takes place. In cells harbouring BRAFV600 mutations, the process leading to MAPK pathway activation is different, and the negative physiological feedback does not exist thus leading to permanent MAPK pathway activation, which ultimately can lead to uncontrolled proliferation...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28157711/the-repurposed-anthelmintic-mebendazole-in-combination-with-trametinib-suppresses-refractory-nrasq61k-melanoma
#7
Cynthia M Simbulan-Rosenthal, Sivanesan Dakshanamurthy, Anirudh Gaur, You-Shin Chen, Hong-Bin Fang, Maryam Abdussamad, Hengbo Zhou, John Zapas, Valerie Calvert, Emanuel F Petricoin, Michael B Atkins, Stephen W Byers, Dean S Rosenthal
Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAFWT and BRAFV600E. We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAFWT-NRASQ61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation. Reverse Phase Protein Array (RPPA) and immunoblot analyses show that both trametinib and MBZ inhibit the MAPK pathway, and cluster analysis revealed a protein cluster showing strong MBZ+trametinib - inhibited phosphorylation of MEK and ERK within 10 minutes, and its direct and indirect downstream targets related to stress response and translation, including ElK1 and RSKs within 30 minutes...
February 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28147313/mapk-pathway-inhibition-induces-met-and-gab1-levels-priming-braf-mutant-melanoma-for-rescue-by-hepatocyte-growth-factor
#8
Sean Caenepeel, Keegan Cooke, Sarah Wadsworth, Guo Huang, Lidia Robert, Blanca Homet Moreno, Giulia Parisi, Elaina Cajulis, Richard Kendall, Pedro Beltran, Antoni Ribas, Angela Coxon, Paul E Hughes
Therapeutic resistance is a major obstacle to achieving durable clinical responses with targeted therapies, highlighting a need to elucidate the underlying mechanisms responsible for resistance and identify strategies to overcome this challenge. An emerging body of data implicates the tyrosine kinase MET in mediating resistance to BRAF inhibitors in BRAFV600E mutant melanoma. In this study we observed a dominant role for the HGF/MET axis in mediating resistance to BRAF and MEK inhibitors in models of BRAFV600E and NRAS mutant melanoma...
January 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28077340/clinicopathological-characteristics-of-papillary-thyroid-cancer-in-children-with-emphasis-on-the-pubertal-status-and-association-with-brafv600e-mutation
#9
Şükran Poyrazoğlu, Rüveyde Bundak, Firdevs Baş, Gülçin Yeğen, Yasemin Şanlı, Feyza Darendeliler
OBJECTIVE: Papillary thyroid cancer (PTC) could behave differently in prepubertal than in pubertal children and between children and adults. BRAF gene activating mutations may associate with PTC by creating aberrant activation. We aimed to evaluate clinicopathological characteristics of PTC patients with emphasis on the pubertal status and investigate the association of BRAFV600E mutation with disease characteristics. METHODS: Medical records of 75 patients with PTC were reviewed retrospectively...
January 12, 2017: Journal of Clinical Research in Pediatric Endocrinology
https://www.readbyqxmd.com/read/28075446/nf%C3%A2-%C3%AE%C2%BAb-inhibition-is-associated-with-opn-mmp%C3%A2-9-downregulation-in-cutaneous-melanoma
#10
Claudio Guarneri, Valentina Bevelacqua, Jerry Polesel, Luca Falzone, Patrizia S Cannavò, Demetrios A Spandidos, Grazia Malaponte, Massimo Libra
The development of cutaneous melanoma is influenced by genetic factors, including BRAF mutations and environmental factors, such as ultraviolet exposure. Its progression has been also associated with the involvement of several tumour microenvironmental molecules. Among these, nuclear factor‑κB (NF‑κB) has been indicated as a key player of osteopontin (OPN) and matrix metalloproteinase‑9 (MMP‑9) activation. However, whether NF‑κB plays a role in the development and progression of melanoma in association with the OPN/MMP‑9 axis according to the BRAFV600E mutation status has not been investigated in detail to date...
February 2017: Oncology Reports
https://www.readbyqxmd.com/read/28073844/fda-approval-of-nivolumab-for-the-first-line-treatment-of-patients-with-brafv600-wild-type-unresectable-or-metastatic-melanoma
#11
Julia A Beaver, Marc R Theoret, Sirisha Mushti, Kun He, Meredith Libeg, Kirsten Goldberg, Rajeshwari Sridhara, Amy E McKee, Patricia Keegan, Richard Pazdur
On November 23, 2015, the U.S. Food and Drug Administration approved nivolumab (OPDIVO®, Bristol Myers Squibb, Co.) as a single agent for the first-line treatment of patients with BRAFV600 wild-type, unresectable or metastatic melanoma. An international, double-blind, randomized (1:1) trial conducted outside of the U.S. allocated 418 patients to receive nivolumab 3mg/kg intravenously every 2 weeks (n=210) or dacarbazine 1000mg/m2 intravenously every 3 weeks (n=208). Patients with disease progression who met protocol-specified criteria (~25% of each trial arm) were permitted to continue with the assigned treatment in a blinded fashion until further disease progression is documented...
January 10, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28058658/combination-treatment-of-patients-with-braf-mutant-melanoma-a-new-standard-of-care
#12
REVIEW
Ester Simeone, Antonio M Grimaldi, Lucia Festino, Vito Vanella, Marco Palla, Paolo A Ascierto
Raf-mitogen-activated protein kinase (Raf-MAPK) pathway inhibition with the BRAF inhibitors vemurafenib and dabrafenib, alone or in combination with a MEK inhibitor, has become a standard therapeutic approach in patients with BRAF-mutated metastatic melanoma. Both vemurafenib and dabrafenib have shown good safety and efficacy as monotherapy compared with chemotherapy. However, the duration of response is limited in the majority of patients treated with BRAF inhibitor monotherapy because of the development of acquired resistance...
February 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28058082/on-chip-wavelength-multiplexed-detection-of-cancer-dna-biomarkers-in-blood
#13
H Cai, M A Stott, D Ozcelik, J W Parks, A R Hawkins, H Schmidt
We have developed an optofluidic analysis system that processes biomolecular samples starting from whole blood and then analyzes and identifies multiple targets on a silicon-based molecular detection platform. We demonstrate blood filtration, sample extraction, target enrichment, and fluorescent labeling using programmable microfluidic circuits. We detect and identify multiple targets using a spectral multiplexing technique based on wavelength-dependent multi-spot excitation on an antiresonant reflecting optical waveguide chip...
November 2016: Biomicrofluidics
https://www.readbyqxmd.com/read/28035401/acy-1215-accelerates-vemurafenib-induced-cell-death-of-braf-mutant-melanoma-cells-via-induction-of-er-stress-and-inhibition-of-erk-activation
#14
Ueihuei Peng, Zhihao Wang, Sa Pei, Yunchao Ou, Pengchao Hu, Wanhong Liu, Jiquan Song
BRAFV600E mutation is found in ~50% of melanoma patients and BRAFV600E kinase activity inhibitor, vemurafenib, has achieved a remarkable clinical response rate. However, most patients treated with vemurafenib eventually develop resistance. Overcoming primary and secondary resistance to selective BRAF inhibitors remains one of the most critically compelling challenges for these patients. HDAC6 has been shown to confer resistance to chemotherapy in several types of cancer. Few studies focused on the role of HDAC6 in vemurafenib resistance...
February 2017: Oncology Reports
https://www.readbyqxmd.com/read/28031237/expression-profiling-of-a-human-thyroid-cell-line-stably-expressing-the-brafv600e-mutation
#15
Byoung-Ae Kim, Hyeon-Gun Jee, Jin Wook Yi, Su-Jin Kim, Young Jun Chai, June Young Choi, Kyu Eun Lee
BACKGROUND/AIM: The BRAF(V600E) mutation acts as an initiator of cancer development in papillary thyroid carcinoma (PTC). Gene expression changes caused by the BRAF(V600E) mutation may have an important role in thyroid cancer development. MATERIALS AND METHODS: To study genomic alterations caused by the BRAF(V600E) mutation, we made human thyroid cell lines that harbor the wild-type BRAF gene (Nthy/WT) and the V600E mutant-type BRAF gene (Nthy/V600E). RESULTS: Flow cytometry and western blotting showed stable transfection of the BRAF gene...
2, 2017: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/28009606/hobnail-variant-of-papillary-thyroid-carcinoma-clinicopathologic-and-molecular-evidence-of-progression-to-undifferentiated-carcinoma-in-2-cases
#16
José M Cameselle-Teijeiro, Irene Rodríguez-Pérez, Ricardo Celestino, Catarina Eloy, Magalí Piso-Neira, Ihab Abdulkader-Nallib, Paula Soares, Manuel Sobrinho-Simões
The hobnail variant (HV) of papillary thyroid carcinoma (PTC) is an unusual entity recently proposed as an aggressive variant of PTC. We describe the pathologic and molecular features of 2 cases of HV of PTC. Both tumors presented in stage III (pT3 pN1a M0). The first case was diagnosed in a 62-year-old man, whereas the second was in a 53-year-old woman. Both patients were treated with total thyroidectomy and radioactive iodine. The primary tumors showed a hobnail/micropapillary pattern in ≥50% of the neoplasm, and positivity for TTF-1, TTF-2, thyroglobulin (TG), cyclin D1, and p53...
December 22, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28006055/association-of-dna-mismatch-repair-and-mutations-in-braf-and-kras-with-survival-after-recurrence-in-stage-iii-colon-cancers-a-secondary-analysis-of-2-randomized-clinical-trials
#17
Frank A Sinicrope, Qian Shi, Carmen J Allegra, Thomas C Smyrk, Stephen N Thibodeau, Richard M Goldberg, Jeffrey P Meyers, Kay L Pogue-Geile, Greg Yothers, Daniel J Sargent, Steven R Alberts
Importance: The association of biomarkers with patient survival after recurrence (SAR) of cancer is poorly understood but may guide management and treatment. Objective: To determine the association of DNA mismatch repair (MMR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27994058/signal-transducer-and-activator-of-transcription-1-plays-a-pivotal-role-in-ret-ptc3-oncogene-induced-expression-of-indoleamine-2-3-dioxygenase-1
#18
Sonia Moretti, Elisa Menicali, Nicole Nucci, Pasquale Voce, Renato Colella, Rosa Marina Melillo, Federica Liotti, Silvia Morelli, Francesca Fallarino, Antonio Macchiarulo, Massimo Santoro, Nicola Avenia, Efisio Puxeddu
Indoleamine 2,3-dioxygenase 1 (IDO1) is a single chain oxidoreductase that catalyzes tryptophan degradation to kynurenine. In cancer, it exerts an immunosuppressive function as part of an acquired mechanism of immune escape. Recently, we demonstrated that IDO1 expression is significantly higher in all thyroid cancer histotypes compared with normal thyroid and that its expression levels correlate with T regulatory (Treg) lymphocyte densities in the tumor microenvironment. BRAF(V600E)- and RET/PTC3-expressing PcCL3 cells were used as cellular models for the evaluation of IDO1 expression in thyroid carcinoma cells and for the study of involved signal transduction pathways...
February 3, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27977682/perk-is-a-haploinsufficient-tumor-suppressor-gene-dose-determines-tumor-suppressive-versus-tumor-promoting-properties-of-perk-in-melanoma
#19
Dariusz Pytel, Yan Gao, Katarzyna Mackiewicz, Yuliya V Katlinskaya, Kirk A Staschke, Maria C G Paredes, Akihiro Yoshida, Shuo Qie, Gao Zhang, Olga S Chajewski, Lawrence Wu, Ireneusz Majsterek, Meenhard Herlyn, Serge Y Fuchs, J Alan Diehl
The unfolded protein response (UPR) regulates cell fate following exposure of cells to endoplasmic reticulum stresses. PERK, a UPR protein kinase, regulates protein synthesis and while linked with cell survival, exhibits activities associated with both tumor progression and tumor suppression. For example, while cells lacking PERK are sensitive to UPR-dependent cell death, acute activation of PERK triggers both apoptosis and cell cycle arrest, which would be expected to contribute tumor suppressive activity...
December 2016: PLoS Genetics
https://www.readbyqxmd.com/read/27974353/vegf-blockade-enhances-the-antitumor-effect-of-brafv600e-inhibition
#20
Valentina Comunanza, Davide Corà, Francesca Orso, Francesca Maria Consonni, Emanuele Middonti, Federica Di Nicolantonio, Anton Buzdin, Antonio Sica, Enzo Medico, Dario Sangiolo, Daniela Taverna, Federico Bussolino
The development of resistance remains a major obstacle to long-term disease control in cancer patients treated with targeted therapies. In BRAF-mutant mouse models, we demonstrate that although targeted inhibition of either BRAF or VEGF initially suppresses the growth of BRAF-mutant tumors, combined inhibition of both pathways results in apoptosis, long-lasting tumor responses, reduction in lung colonization, and delayed onset of acquired resistance to the BRAF inhibitor PLX4720. As well as inducing tumor vascular normalization and ameliorating hypoxia, this approach induces remodeling of the extracellular matrix, infiltration of macrophages with an M1-like phenotype, and reduction in cancer-associated fibroblasts...
February 2017: EMBO Molecular Medicine
keyword
keyword
83954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"